A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma

OBJECTIVE: We evaluated ibrutinib, a once‐daily inhibitor of Bruton's tyrosine kinase, combined with bortezomib and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma who had received 1‐3 prior therapies. METHODS: This was a phase 2, single‐arm, open‐label, multicen...

Descripción completa

Detalles Bibliográficos
Autores principales: Hajek, Roman, Pour, Ludek, Ozcan, Muhit, Martin Sánchez, Jesus, García Sanz, Ramon, Anagnostopoulos, Achilles, Oriol, Albert, Cascavilla, Nicola, Terjung, Andreas, Lee, Yihua, Briso, Eva M., Dobkowska, Edyta, Hauns, Bernhard, Špička, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216833/
https://www.ncbi.nlm.nih.gov/pubmed/31883396
http://dx.doi.org/10.1111/ejh.13377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216833/
https://www.ncbi.nlm.nih.gov/pubmed/31883396
http://dx.doi.org/10.1111/ejh.13377

Ejemplares similares